A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on sleep and related health outcomes.
This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States. Eligible participants will (1) endorse a desire for better sleep, (2) have the opportunity for meaningful improvement (at least 20%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded. Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
1,646
Participants will use their Radicle Rest Placebo Control Form 1 as directed for a period of 6 weeks.
Participants will use their Radicle Rest Active Study Product 1.1 as directed for a period of 6 weeks.
Participants will use their Radicle Rest Placebo Control Form 2 as directed for a period of 6 weeks.
Radicle Science, Inc
Del Mar, California, United States
Change in sleep
Mean difference in sleep score as assessed by Patient Reported Outcome Measurement System (PROMIS) Sleep Disturbance Short Form 8A (scale 8-40; where higher scores correspond to greater sleep disturbance)
Time frame: 6 weeks
Change in feelings of anxiety
Mean difference in anxiety score as assessed by Patient Reported Outcome Measurement System (PROMIS) Anxiety 4A (scale 4-20; with higher scores corresponding to more severe anxiety)
Time frame: 6 weeks
Change in fatigue
Mean difference in fatigue score as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 4A (scale 4-20; where higher scores correspond to more severe fatigue)
Time frame: 6 weeks
Change in mood (emotional distress-depression)
Mean difference in emotional distress score as assessed by Patient Reported Outcome Measurement System (PROMIS) Emotional Distress- Depression 4A (scale 4-20; with higher scores corresponding to greater levels of emotional distress)
Time frame: 6 weeks
Minimal clinically important difference (MCID) in sleep
Likelihood of experiencing minimal clinically important difference in sleep score as assessed by Patient Reported Outcome Measurement System (PROMIS) Sleep Disturbance Short Form 8A (scale 8-40; where higher scores correspond to greater sleep disturbance)
Time frame: 6 weeks
Minimal clinically important difference (MCID) in feelings of anxiety
Likelihood of experiencing minimal clinically important difference in feelings of anxiety score as assessed by Patient Reported Outcome Measurement System (PROMIS) Anxiety 4A (scale 4-20; with higher scores corresponding to more severe anxiety)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Participants will use their Radicle Rest Active Study Product 2.1 as directed for a period of 6 weeks.
Participants will use their Radicle Rest Active Study Product 4.1.1 as directed for a period of 6 weeks.
Participants will use their Radicle Rest Active Study Product 4.1.1 as directed for a period of 6 weeks.
Time frame: 6 weeks
Minimal clinically important difference (MCID) in fatigue
Likelihood of experiencing minimal clinically important difference in fatigue score as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 4A (scale 4-20; where higher scores correspond to more severe fatigue)
Time frame: 6 weeks
Minimal clinically important difference (MCID) in mood (emotional distress-depression)
Likelihood of experiencing minimal clinically important difference in mood score as assessed by Patient Reported Outcome Measurement System (PROMIS) Emotional Distress- Depression 4A (scale 4-20; with higher scores corresponding to greater levels of emotional distress)
Time frame: 6 weeks